223 related articles for article (PubMed ID: 31797023)
1. Performance of liver surface nodularity quantification for the diagnosis of portal hypertension in patients with cirrhosis: comparison between MRI with hepatobiliary phase sequences and CT.
De Vos N; Sartoris R; Cauchy F; Rautou PE; Vilgrain V; Ronot M
Abdom Radiol (NY); 2020 Feb; 45(2):365-372. PubMed ID: 31797023
[TBL] [Abstract][Full Text] [Related]
2. Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma.
Souhami A; Sartoris R; Rautou PE; Cauchy F; Bouattour M; Durand F; Giannelli V; Gigante E; Castera L; Valla D; Soubrane O; Vilgrain V; Ronot M
JHEP Rep; 2020 Oct; 2(5):100147. PubMed ID: 32885156
[TBL] [Abstract][Full Text] [Related]
3. Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension.
Sartoris R; Rautou PE; Elkrief L; Pollorsi G; Durand F; Valla D; Spahr L; Terraz S; Soubrane O; Cauchy F; Vilgrain V; Ronot M
Radiology; 2018 Dec; 289(3):698-707. PubMed ID: 30179109
[TBL] [Abstract][Full Text] [Related]
4. CT-based liver surface nodularity for the detection of clinically significant portal hypertension: defining measurement quality criteria.
Sartoris R; Lazareth M; Nivolli A; Dioguardi Burgio M; Vilgrain V; Ronot M
Abdom Radiol (NY); 2020 Sep; 45(9):2755-2763. PubMed ID: 32270261
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and reproducibility of liver surface nodularity quantification for the assessment of liver cirrhosis using CT and MRI.
Lo GC; Besa C; King MJ; Kang M; Stueck A; Thung S; Wagner M; Smith AD; Taouli B
Eur J Radiol Open; 2017; 4():95-100. PubMed ID: 28761907
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of Clinically Significant Portal Hypertension Using CT- and MRI-based Vascular Model.
Wang C; Huang Y; Liu C; Liu F; Hu X; Kuang X; An W; Liu C; Liu Y; Liu S; He R; Wang H; Qi X
Radiology; 2023 Apr; 307(2):e221648. PubMed ID: 36719293
[TBL] [Abstract][Full Text] [Related]
7. Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR.
Caparroz C; Forner A; Rimola J; Darnell A; García-Criado Á; Ayuso JR; Reig M; Bruix J; Ayuso C
Radiol Oncol; 2022 Aug; 56(3):292-302. PubMed ID: 35776837
[TBL] [Abstract][Full Text] [Related]
8. Liver Surface Nodularity Quantification from Routine CT Images as a Biomarker for Detection and Evaluation of Cirrhosis.
Smith AD; Branch CR; Zand K; Subramony C; Zhang H; Thaggard K; Hosch R; Bryan J; Vasanji A; Griswold M; Zhang X
Radiology; 2016 Sep; 280(3):771-81. PubMed ID: 27089026
[TBL] [Abstract][Full Text] [Related]
9. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study.
Liu F; Ning Z; Liu Y; Liu D; Tian J; Luo H; An W; Huang Y; Zou J; Liu C; Liu C; Wang L; Liu Z; Qi R; Zuo C; Zhang Q; Wang J; Zhao D; Duan Y; Peng B; Qi X; Zhang Y; Yang Y; Hou J; Dong J; Li Z; Ding H; Zhang Y; Qi X
EBioMedicine; 2018 Oct; 36():151-158. PubMed ID: 30268833
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
[TBL] [Abstract][Full Text] [Related]
12. Evidence of diagnostic enhancement pattern in hepatocellular carcinoma nodules ≤2 cm according to the AASLD/EASL revised criteria.
Quaia E; De Paoli L; Angileri R; Pizzolato R; Cabibbo B; Cova MA
Abdom Imaging; 2013 Dec; 38(6):1245-53. PubMed ID: 24026173
[TBL] [Abstract][Full Text] [Related]
13. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
[TBL] [Abstract][Full Text] [Related]
14. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase.
Quaia E; De Paoli L; Pizzolato R; Angileri R; Pantano E; Degrassi F; Ukmar M; Cova MA
AJR Am J Roentgenol; 2013 Mar; 200(3):553-62. PubMed ID: 23436844
[TBL] [Abstract][Full Text] [Related]
15. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
[TBL] [Abstract][Full Text] [Related]
16. Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: A study of 326 patients from India.
Kumar A; Khan NM; Anikhindi SA; Sharma P; Bansal N; Singla V; Arora A
World J Gastroenterol; 2017 Jan; 23(4):687-696. PubMed ID: 28216976
[TBL] [Abstract][Full Text] [Related]
17. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
[TBL] [Abstract][Full Text] [Related]
18. Gadobenate dimeglumine-enhanced magnetic resonance imaging can accurately predict the severity of esophageal varices and portal vein pressure in patients with hepatitis B cirrhosis.
Feng Q; Guan S; Zhao JR; Zhao XY; Zhang CC; Wang L; Feng YM; Li SL; Zhu Q
J Dig Dis; 2020 Feb; 21(2):104-111. PubMed ID: 31922658
[TBL] [Abstract][Full Text] [Related]
19. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
[TBL] [Abstract][Full Text] [Related]
20. Performance of native and gadoxetate-enhanced liver and spleen T
Altinmakas E; Bane O; Hectors SJ; Issa R; Carbonell G; Abboud G; Schiano TD; Thung S; Fischman A; Kelly MD; Friedman SL; Kennedy P; Taouli B
Abdom Radiol (NY); 2022 Nov; 47(11):3758-3769. PubMed ID: 36085378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
